A modified toxicity probability interval method for dose-finding trials.

نویسندگان

  • Yuan Ji
  • Ping Liu
  • Yisheng Li
  • B Nebiyou Bekele
چکیده

BACKGROUND Building on earlier work, the toxicity probability interval (TPI) method, we present a modified TPI (mTPI) design that is calibration-free for phase I trials. PURPOSE Our goal is to improve the trial conduct and provide more effective designs while maintaining the simplicity of the original TPI design. METHODS Like the TPI method, the mTPI consists of a practical dose-finding scheme guided by the posterior inference for a simple Bayesian model. However, the new method proposes improved dose-finding decision rules based on a new statistic, the unit probability mass (UPM). For a given interval and a probability distribution, the UPM is defined as the ratio of the probability mass of the interval to the length of the interval. RESULTS The improvement through the use of the UPM for dose finding is threefold: (1) the mTPI method appears to be safer than the TPI method in that it puts fewer patients on toxic doses; (2) the mTPI method eliminates the need for calibrating two key parameters, which is required in the TPI method and is a known difficult issue; and (3) the mTPI method corresponds to the Bayes rule under a decision theoretic framework and possesses additional desirable large- and small-sample properties. LIMITATION The proposed method is applicable to dose-finding trials with a binary toxicity endpoint. CONCLUSION The new method mTPI is essentially calibration free and exhibits improved performance over the TPI method. These features make the mTPI a desirable choice for the design of practical trials.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials.

We develop a novel dose-finding method for two-agent combination phase I trials on the basis of the shrunken predictive probability of toxicity. In this method, a shrinkage logistic regression model that allows distinct shrinkage multipliers for the coefficients of the main effects of two agents and their interaction on the probability of toxicity constructs the toxicity outcome. We also propos...

متن کامل

Dose finding with longitudinal data: simpler models, richer outcomes.

Phase I oncology clinical trials are designed to identify the optimal dose that will be recommended for phase II trials. This dose is typically defined as the dose associated with a certain probability of severe toxicity at cycle 1, although toxicity is repeatedly measured over cycles on an ordinal scale. Recently, a proportional odds mixed-effect model for ordinal outcomes has been proposed to...

متن کامل

Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.

A dose-schedule-finding trial is a new type of oncology trial in which investigators aim to find a combination of dose and treatment schedule that has a large probability of efficacy yet a relatively small probability of toxicity. We demonstrate that a major difference between traditional dose-finding and dose-schedule-finding trials is that while the toxicity probabilities follow a simple nond...

متن کامل

Dose-finding in phase I clinical trials based on toxicity probability intervals.

BACKGROUND Most phase I clinical trials conducted at the M. D. Anderson Cancer Center use the algorithmic 3 + 3 design, despite the availability of more advanced model-based designs such as the continual reassessment method. PURPOSE Through simple statistical modeling and computing, we develop a dose-finding design that can be easily understood and implemented by non-statisticians. METHODS ...

متن کامل

Establish the Maximum Tolerated Dose in Phase-I Trials using 3+3 Method

The main goal of Phase-I cancer clinical trials is to find the maximum tolerated dose (MTD) of a drug for Phase-II trial for a specific mode of administration. In Phase-I trials there is a critical need to establish MTD by using minimum possible number of patients so as to avoid exposing too many patients to sub-therapeutic doses while preserving safety and maintaining rapid accrual. 3+3 is a p...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Clinical trials

دوره 7 6  شماره 

صفحات  -

تاریخ انتشار 2010